Clinical Trial Update: Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating eszopiclone for sleep disturbance and nightmares in post-traumatic stress disorder was completed. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Lunesta (eszopiclone)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Post-Traumatic Stress Disorders | Phase 4 | Status: COMPLETED | Results posted: 2014-02-12